Elixinol Wellness Ltd · ASX:EXL
Elixinol Wellness — FY2018 Earnings Presentation
28 slides from Elixinol Wellness's earnings presentation, Feb 26, 2019
Slide 1: Elixinol Global Limited FY2018 full year results
Elixinol Global Limited FY2018 full year results ASX: EXL, OTCQX: ELLXF | www.elixinolglobal.com
Slide 2: Disclaimer
Disclaimer This presentation contains summary information about Elixinol Global Limited (EXL) and its subsidiaries and their activities. The information in this presentation does not purport to be complete. It should be read in conjunction with EXL’s other periodic and continuous disclosure announce
Slide 3: Agenda
Agenda Cannabis definition 4 Who we are 5 Key highlights for financial results FY2018 7 Business overview 9 Financial results FY2018 18 Outlook 22 Q+A 25 Appendix 26 www.elixinolglobal.com
Slide 4: Cannabis Definition
Cannabis Who w e Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results 4 EXL | FY2018 Results Presentation
Slide 5: Who we are
Cannabis Who w e Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Who we are Benefiting health and wellness in communities around the world Elixinol Global (herein referred to as EXL) is a global consumer brand with products in multiple cannabis verticals, inclu
Slide 6: Why we're different
Cannabis Who w e Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Why we’re different We believe our products represent the highest quality in the market • Widely recognised global brand with industry leading products delivered in multiple form factors • Vertica
Slide 7: Key highlights for FY2018
Key highlights for FY2018 www.elixinolglobal.com
Slide 8: Key highlights for FY2018 (December 31 year end)
Cannabis Who w e Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Key highlights for FY2018 (December 31 year end) 1 Revenue FY2018 $37.1m vs FY2017 $16.8m, 121% growth Group results Underlying EBITDA FY2018 $0.7m vs FY2017 breakeven FY2018 Underlying NPAT FY201
Slide 9: Business overview
Business overview www.elixinolglobal.com
Slide 10: Diversified portfolio
Cannabis Who w e Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Diversified portfolio FY2018 revenue by business unit Consumer Products Pharmaceutical Dietary Supplements Hemp Foods Medicinal Cannabis Revenue $32.5m (87%)* Revenue $4.9m (13%)* Seeking licence
Slide 11: Strong growth trajectory across key metrics
Cannabis Who w e Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Strong grow th trajectory across key metrics EXL has maintained a strong growth trajectory Revenue Underlying EBITDA A$ million, 31 December year end A$ million, 31 December year end $50 $40 37.1
Slide 12: Revenue growth by Consumer Products segment
Cannabis Who w e Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Revenue grow th by Consumer Products segment Growth across all revenue segments with a clear strategy to drive higher margin products Elixinol USA Hemp Foods Australia A$ million, 31 December year
Slide 13: Elixinol Global key growth initiatives
Cannabis Who w e Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Elixinol Global key grow th initiatives Continued disciplined approach to drive future revenue growth ✓ Investment in farming and production capabilities to facilitate future growth ✓ Key sales hi
Slide 14: Elixinol Global, international footprint
Cannabis Who w e Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Elixinol Global, international footprint An established platform that can be leveraged for consumer products Global platform for growth • Avenues to market established across • Operations (pins) i
Slide 15: Growth Drivers: Elixinol
Cannabis Who w e Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Grow th Drivers: Elixinol Firmly positioned to drive revenue growth and take CBD market share • Doubling production capacity in the USA with new 12,000 sq. ft. square foot Colorado facility (to be
Slide 16: Growth Drivers: Hemp Foods Australia
Cannabis Who w e Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Grow th Drivers: Hemp Foods Australia Leveraging industry leading position in Australia to further accelerate growth • Solidify #1 market position in Australia for hemp food branded • Launched new
Slide 17: Growth Drivers: Nunyara Pharma (Australia)
Cannabis Who w e Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Grow th Drivers: Nunyara Pharma (Australia) Leveraging US cannabinoid production and formulation expertise for Medical Cannabis Subject to ODC licences and planning approvals: • The planned facili
Slide 18: FY2018 financial results
FY2018 financial results www.elixinolglobal.com
Slide 19: Financial summary
Cannabis Who w e Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Financial summary Building scale to support expected future growth ($m) FY2018 FY2017 ($m) FY2018 FY2017 Commentary ($m) Revenue FY2018 37.1 FY2017 16.8 Revenue Cost of goods sold (17.2) (6.3) • g
Slide 20: Cash flow
Cannabis Who w e Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Cash flow Re-investment to facilitate expected future growth ($m) FY2018 FY2017 Commentary Operating activities (5.7) (1.2) Operating cash flow Investing activities (8.5) (0.5) • working capital e
Slide 21: Strong financial position
Cannabis Who w e Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Strong financial position Strong cash position and minimal debt ($m) 31 Dec 2018 31 Dec 2017 Commentary Current assets Strong cash position Cash and cash equivalents 42.9 18.8 • strong net cash po
Slide 22: Outlook
Outlook www.elixinolglobal.com
Slide 23: Outlook
Cannabis Who w e Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Outlook Paul Benhaim, CEO Elixinol Global stated: “ We are very pleased with our revenue growth of 121% for FY2018 across our businesses globally. Meetings with large national outlets have indicat
Slide 24: Strategic outlook: delivering on our corporate strategy
Cannabis Who w e Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Strategic outlook: delivering on our corporate strategy Capturing substantial global growth opportunity in hemp- CBD and medicinal cannabis FY2021 • Global top 3 leadership FY2020 position in CBD
Slide 25: Q&A
Q&A www.elixinolglobal.com
Slide 26: Appendix
Appendix www.elixinolglobal.com
Slide 27: Reconciliation to FY2018 underlying EBITDA and NPAT
Cannabis Who w e Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Reconciliation to FY2018 underlying EBITDA and NPAT ($m) FY2018 Statutory NPAT (0.9) Tax expense 0.4 Depreciation & amortisation 0.8 Interest income/finance costs (0.4) Statutory EBITDA (0.1) Shar
Slide 28: For more information
For more information: Investor relations and media please contact: Australia United States of America Glen Zurcher Cody Slach Account Director, IR Department Managing Director, Liolios Group Inc IR@elixinolglobal.com | +61 420 249 299 USIR@elixinolglobal.com | +1 949 574 3860 www.elixinolglobal.com